Disease, Pharmaceutical Companies, Structure Based Drug Design (SBDD) and Treatment

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Disease

Pharmaceutical Companies

Structure Based Drug Design (SBDD)

Treatment

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. References.

Small Molecule

Small Molecule Structure Based Drug Design (SBDD) International Molecular Biology

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. Captor’s Optigradeä platform is focused on improving the selectivity and performance of first-generation degrader drugs.

Targeted Protein Degradation

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs

Drug Discovery Digest

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

Stay Connected